丸美生物
(603983)
| 流通市值：134.50亿 | | | 总市值：134.50亿 |
| 流通股本：4.01亿 | | | 总股本：4.01亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,450,380,539.41 | 1,764,646,729.2 | 846,648,701.63 | 2,969,770,566.54 |
| 营业收入 | 2,450,380,539.41 | 1,764,646,729.2 | 846,648,701.63 | 2,969,770,566.54 |
| 二、营业总成本 | 2,206,220,208.73 | 1,550,885,924.71 | 684,279,945.76 | 2,610,212,848.29 |
| 营业成本 | 614,706,979.79 | 448,184,341.2 | 202,740,941.83 | 781,028,905.06 |
| 税金及附加 | 28,878,373.64 | 13,465,361.25 | 6,454,631.6 | 26,499,988.87 |
| 销售费用 | 1,414,567,358.33 | 999,196,374.25 | 441,717,448.89 | 1,634,676,977.95 |
| 管理费用 | 101,172,990.99 | 60,753,973.5 | 24,533,886.45 | 108,516,380.48 |
| 研发费用 | 62,788,807.55 | 39,964,788.86 | 15,927,066.39 | 73,544,828.78 |
| 财务费用 | -15,894,301.57 | -10,678,914.35 | -7,094,029.4 | -14,054,232.85 |
| 其中:利息费用 | 2,689,869.53 | 2,656,560.66 | 866,083.3 | 9,857,665.96 |
| 其中:利息收入 | 18,928,874.75 | 13,364,648.6 | 7,992,870.12 | 24,411,967.64 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 22,698,859.7 | 587,598.74 | 189,317.92 | -982,898.54 |
| 加:投资收益 | 16,823,669.04 | 2,783,249.38 | 1,526,876.83 | 20,024,755.1 |
| 资产处置收益 | 377,398.06 | 377,398.06 | 382,013.03 | 29,631.89 |
| 资产减值损失(新) | -1,715,369.91 | -1,349,645.31 | -819,952.73 | -12,233,506.16 |
| 信用减值损失(新) | 319,316.89 | 228,622.4 | -225,474.27 | 159,077.08 |
| 其他收益 | 16,412,852.63 | 12,732,895.09 | 2,562,014.1 | 14,382,032.6 |
| 四、营业利润 | 299,077,057.09 | 229,120,922.85 | 165,983,550.75 | 380,936,810.22 |
| 加:营业外收入 | 570,962.23 | 383,317.79 | 175,884.7 | 325,605.08 |
| 减:营业外支出 | 1,126,541.95 | 651,743.16 | 7,947.65 | 605,906.34 |
| 五、利润总额 | 298,521,477.37 | 228,852,497.48 | 166,151,487.8 | 380,656,508.96 |
| 减:所得税费用 | 51,872,160.73 | 54,140,050.44 | 30,953,790.62 | 38,292,618.64 |
| 六、净利润 | 246,649,316.64 | 174,712,447.04 | 135,197,697.18 | 342,363,890.32 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 246,649,316.64 | 174,712,447.04 | 135,197,697.18 | 342,363,890.32 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 243,892,254.22 | 174,410,644.57 | 135,045,089.33 | 341,628,707.73 |
| 少数股东损益 | 2,757,062.42 | 301,802.47 | 152,607.85 | 735,182.59 |
| 扣除非经常损益后的净利润 | 214,069,755.26 | 166,044,031.92 | 134,079,492.17 | 326,575,322.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.61 | 0.43 | 0.34 | 0.85 |
| (二)稀释每股收益 | 0.61 | 0.43 | 0.34 | 0.85 |
| 八、其他综合收益 | -73,087.1 | -112,116.33 | -59,597.35 | -124,364.71 |
| 归属于母公司股东的其他综合收益 | -73,087.1 | -112,116.33 | -59,597.35 | -124,364.71 |
| 九、综合收益总额 | 246,576,229.54 | 174,600,330.71 | 135,138,099.83 | 342,239,525.61 |
| 归属于母公司股东的综合收益总额 | 243,819,167.12 | 174,298,528.24 | 134,985,491.98 | 341,504,343.02 |
| 归属于少数股东的综合收益总额 | 2,757,062.42 | 301,802.47 | 152,607.85 | 735,182.59 |
| 公告日期 | 2025-10-31 | 2025-08-23 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |